Latest period
$3.68B
YoY change
-18.0%
5Y CAGR
+7.8%
Peak year (2024)
$4.38B
Latest annual
$3.59B
Total Liabilities history chart for DexCom (DXCM) from 2000 to 2025
Latest: $3.59B
Total Liabilities growth chart for DexCom (DXCM) from 2000 to 2025
Latest: -18.0%
Total Liabilities history table for DexCom (DXCM) from 2000 to 2025
| 2025 | $3.59B | -18.0% | −$788.00M | ||
| 2024 | $4.38B | +4.4% | +$186.00M | ||
| 2023 | $4.20B | +28.7% | +$936.00M | ||
| 2022 | $3.26B | +12.8% | +$368.70M | ||
| 2021 | $2.89B | +17.3% | +$427.20M | ||
| 2020 | $2.46B | +62.9% | +$951.60M | ||
| 2019 | $1.51B | +20.7% | +$259.70M | ||
| 2018 | $1.25B | +158.4% | +$768.00M | ||
| 2017 | $484.70M | +307.3% | +$365.70M | ||
| 2016 | $119.00M | +68.1% | +$48.20M | ||
| 2015 | $70.80M | +59.5% | +$26.40M | ||
| 2014 | $44.40M | +15.6% | +$6.00M | ||
| 2013 | $38.40M | +32.4% | +$9.40M | ||
| 2012 | $29.00M | +81.4% | +$13.02M | ||
| 2011 | $15.98M | -1.2% | −$186.00K | ||
| 2010 | $16.17M | -75.3% | −$49.22M | ||
| 2009 | $65.39M | -21.2% | −$17.59M | ||
| 2008 | $82.98M | +18.3% | +$12.84M | ||
| 2007 | $70.14M | +808.1% | +$62.42M | ||
| 2006 | $7.72M | +5.6% | +$410.15K | ||
| 2005 | $7.31M | -90.7% | −$71.35M | ||
| 2004 | $78.67M | +47.4% | +$25.30M | ||
| 2003 | $53.37M | — | — | ||
| 2001 | $0.00 | — | $0.00 | ||
| 2000 | $0.00 | — | — |
- 2025$3.59B-18.0%
- 2024$4.38B+4.4%
- 2023$4.20B+28.7%
- 2022$3.26B+12.8%
- 2021$2.89B+17.3%
- 2020$2.46B+62.9%
- 2019$1.51B+20.7%
- 2018$1.25B+158.4%
- 2017$484.70M+307.3%
- 2016$119.00M+68.1%
- 2015$70.80M+59.5%
- 2014$44.40M+15.6%
- 2013$38.40M+32.4%
- 2012$29.00M+81.4%
- 2011$15.98M-1.2%
- 2010$16.17M-75.3%
- 2009$65.39M-21.2%
- 2008$82.98M+18.3%
- 2007$70.14M+808.1%
- 2006$7.72M+5.6%
- 2005$7.31M-90.7%
- 2004$78.67M+47.4%
- 2003$53.37M—
- 2001$0.00—
- 2000$0.00—
Total Liabilities values are taken from DexCom's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Liabilities at DexCom (DXCM)
According to DexCom's latest reported financial statements, the company's latest reported total liabilities is $3.68B. Total liabilities sum everything the company owes at the end of each reporting period — accounts payable, accrued expenses, debt, lease obligations, and other claims — as filed on the balance sheet. Compare with total assets and total equity for solvency context.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
In 2025, DexCom (DXCM) total liabilities totalled $3.59B – declined 18.0% year-over-year.
Looking at the 2020–2025 (5 years) stretch, DexCom total liabilities compounded at +7.8% per year, with mixed annual results across the window.
2024 marks the peak total liabilities at $4.38B, with the historical low of $0.00 recorded in 2000.
DexCom Total Liabilities by Year
DexCom Total Liabilities 2025: $3.59B
In 2025, DexCom reported total liabilities of $3.59B, declined 18.0% below 2024.
DexCom Total Liabilities 2024: $4.38B
DexCom total liabilities in 2024 was $4.38B, edged up 4.4% from 2023. This figure represents the highest annual value in the available history.
DexCom Total Liabilities 2023: $4.20B
2023's total liabilities for DexCom came in at $4.20B, grew 28.7% from 2022.
DexCom Total Liabilities 2022: $3.26B
DexCom posted total liabilities of $3.26B in 2022, grew 12.8% from 2021.
DexCom Total Liabilities 2021: $2.89B
DexCom total liabilities in 2021 was $2.89B.
See more financial history for DexCom (DXCM).
Sector peers by Total Liabilities
Healthcare peers of DexCom (DXCM), ranked by their latest total liabilities
| $207.88B | |
| $137.19B | |
| $117.67B | |
| $85.94B | |
| $84.20B | |
| $81.93B | |
| $65.36B | |
| $54.86B |
- $207.88B
- $137.19B
- $117.67B
- $85.94B
- $84.20B
- $81.93B
- $65.36B
- $54.86B
Frequently asked questions
DexCom (DXCM) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation